Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2Hematologic Neoplasms 1

Interventions

Bevacizumab 187Fluorouracil 150Leucovorin 135Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43Nivolumab 43regorafenib 42Folfox protocol 39Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 23Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × bermekimab × Clear all
NCT01767857 2021-06-29

XCITE

Janssen Research & Development, LLC

Phase 3 Terminated
643 enrolled 16 charts
Gastrointestinal

Colorectal Neoplasms

NCT02138422 2021-03-01

A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer

Janssen Research & Development, LLC

Phase 3 Completed
276 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡